Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 14/20 | 0.43 |
| ▸ | SCN7A | Q01118 | 4/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.43 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6181357 | 0.88 | MAPKAPK2 (0.54) | SCN9ASCN7AKCNH2MAPKAPK2 | |
| SCHEMBL9114545 | 0.78 | ESR2 (0.57) | ESR2 | |
| SCHEMBL6181567 | 0.76 | ESR2 (0.52) | ESR2SCN9A | |
| SCHEMBL23141346 | 0.75 | ESR2 (0.81) | ESR2 | |
| SCHEMBL1897244 | 0.74 | CA12 (0.52) | ESR2SCN9ASCN7AKCNH2 | |
| SCHEMBL4315032 | 0.73 | CA12 (0.73) | ESR2 | |
| SCHEMBL6183263 | 0.73 | MMP13 (0.57) | — | |
| SCHEMBL11900203 | 0.70 | ESR2 (0.62) | ESR2 | |
| SCHEMBL11016232 | 0.69 | ESR2 (0.47) | ESR2 | |
| SCHEMBL3137167 | 0.67 | ESR2 (1.00) | ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919332-B2 | N-substituted-heteroaryloxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors | PFIZER INC. (US) | 2005-07-19 | — | — | US | disclosed |
| EP-1507535-A1 | PYRIMIDINE-2,4,6-TRIONE METALLO-PROTEINASE INHIBITORS | Pfizer Products Inc. (US) | 2005-02-23 | — | — | EP | disclosed |
| US-20030232849-A1 | N-substituted-heteroaryloxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors | PFIZER INC. | 2003-12-18 | — | — | US | disclosed |
| WO-2003090751-A1 | PYRIMIDINE-2, 4, 6-TRIONE METALLO-PROTEINASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232849-A1 | N-substituted-heteroaryloxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors | MMP8, MMP9, MMP1 | ESR2 742/4885SCN9A 4121/4885SCN7A 3730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.